Gerald Quirk Net Worth

The estimated Net Worth of Gerald E Quirk is at least $1.54 million dollars as of 27 March 2024. Mr. Quirk owns over 22,500 units of Syros Pharmaceuticals stock worth over $75,353 and over the last 15 years he sold SYRS stock worth over $0. In addition, he makes $1,460,190 as Chief Legal & Administrative Officer at Syros Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Quirk SYRS stock SEC Form 4 insiders trading

Gerald has made over 2 trades of the Syros Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 22,500 units of SYRS stock worth $36,225 on 27 March 2024.

The largest trade he's ever made was exercising 22,500 units of Syros Pharmaceuticals stock on 27 March 2024 worth over $36,225. On average, Gerald trades about 3,462 units every 13 days since 2010. As of 27 March 2024 he still owns at least 46,803 units of Syros Pharmaceuticals stock.

You can see the complete history of Mr. Quirk stock trades at the bottom of the page.

Gerald Quirk biography

Gerald E. Quirk Esq. J.D. serves as Chief Legal & Administrative Officer of the Company. He has served as our chief legal officer from September 2016 to June 2017 and as our chief legal and administrative officer since June 2017. He previously served as executive vice president, business operations and general counsel of Tokai Pharmaceuticals, Inc., a biotechnology company, from May 2015 to August 2016. Prior to that, Mr. Quirk was a partner and co-chair of the life sciences practice at Choate, Hall & Stewart LLP, a Boston law firm, from August 2012 until May 2015. Mr. Quirk previously served as vice president, corporate affairs and general counsel at Infinity Pharmaceuticals, Inc. from August 2006 until August 2012, and prior to that held legal and business development positions of increasing responsibility at Genzyme Corporation. Mr. Quirk holds a B.A. in political science from Swarthmore College, an Ed.M. in educational administration from Harvard University, and a J.D. from Northeastern University.

What is the salary of Gerald Quirk?

As the Chief Legal & Administrative Officer of Syros Pharmaceuticals, the total compensation of Gerald Quirk at Syros Pharmaceuticals is $1,460,190. There are 5 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.

How old is Gerald Quirk?

Gerald Quirk is 52, he's been the Chief Legal & Administrative Officer of Syros Pharmaceuticals since 2017. There are 15 older and 3 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.

What's Gerald Quirk's mailing address?

Gerald's mailing address filed with the SEC is 35 CAMBRIDGEPARK DRIVE, , CAMBRIDGE, MA, 02140.

Insiders trading at Syros Pharmaceuticals

Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju et Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.

What does Syros Pharmaceuticals do?

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Complete history of Mr. Quirk stock trades at Infinity Pharmaceuticals et Syros Pharmaceuticals

Syros Pharmaceuticals executives and stock owners

Syros Pharmaceuticals executives and other stock owners filed with the SEC include:

• Nancy Simonian,
  President, Chief Executive Officer, Director
• Joseph Ferra,
  Chief Financial Officer
• Jeremy Springhorn,
  Chief Business Officer
• David Roth,
  Chief Medical Officer
• Eric Olson,
  Chief Scientific Officer
• Gerald Quirk,
  Chief Legal & Administrative Officer
• Dr. Nancy A. Simonian M.D.,
  Pres, CEO & Director
• Dr. David A. Roth,
  Chief Medical Officer
• Dr. Eric R. Olson,
  Chief Scientific Officer
• Richard Young,
  Director
• Dr. Richard A. Young Ph.D.,
  Scientific Founder, Member of Scientific Advisory Board & Director
• Mark Alles,
  Independent Director
• Peter Wirth,
  Independent Chairman of the Board
• Marsha Fanucci,
  Independent Director
• Amir Nashat,
  Independent Director
• Phillip Sharp,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Hannah Deresiewicz,
  IR Contact Officer
• S. Gail Eckhardt,
  Director
• Dr. Christian C. Fritz Ph.D.,
  Head of Biology
• Naomi Aoki,
  VP of Corp. Communications & Investor Relations
• Gerald E. Quirk,
  Chief Operations Officer & Sec.
• Jason Haas,
  Chief Financial Officer
• Dr. Nathanael S. Gray Ph.D.,
  Scientific Founder & Member of Scientific Advisory Board
• Dr. James E. Bradner M.D.,
  Founder
• Alice Tsang Shaw,
  Director
• Ventures Fund Iv, L.P.Flags...,
  
• Sanj K Patel,
  Director
• Vicki L Sato,
  Director
• Michael W Bonney,
  Director
• Colleen Elizabeth De Simone,
  Principal Accounting Officer
• Robert Nelsen,
  Director
• Venture Fund Vii, L.P.Arch ...,
  
• Kyle D. Kuvalanka,
  Chief Operating Officer
• Stephane Bancel,
  Director
• Management Co. Vii, L.L.C.P...,
  
• Pharm Tech Healthcare Fund ...,
  10% owner
• Group, Llc Green Jeremy Red...,
  
• Venture Fund Vii Lparch Ven...,
  
• Healthcare Ventures Ii, L.P...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Kristin Stephens,
  Chief Development Officer
• Deborah Dunsire,
  
• Jason Haas,
  Chief Financial Officer
• Timothy Tyson,
  
• Conley Chee,
  President & CEO
• Andrew M. Oh,